March 29, 2024
cancer
cancer
The FDA approved Keytruda for a range of cancers with a common biomarker. At right, Dr. Thomas George, associate director of clinical investigation at University of Florida Health Cancer Center.

Cancer Care

Wider Approval

The FDA takes a broader approach to approving drug therapy.

Amy Martinez | 2/27/2018

Historically, the FDA has approved cancer drugs based on a particular cancer’s location in the body, but that may be changing.

Last year, the FDA said Keytruda, a new immunotherapy drug by Merck, could be used to treat all cancers that share a genetic abnormality called mismatch repair (MMR) deficiency. It was the first time the FDA approved a cancer drug based on a common biomarker rather than the cancer type — lung vs. breast, for example. Keytruda itself previously had been approved for patients with metastatic lung, neck and skin cancers.

The immunotherapy targets proteins on T-cells that prevent a patient’s immune system from recognizing and attacking cancer cells. By blocking these proteins, Keytruda aims to increase the im- mune system’s ability to home in on cancer cells without harming normal, healthy tissue. About 40% of cancer patients who received Keytruda in clinical trials saw their tumors shrink or disappear.

Doctors estimate that 4% of all cancers are MMR deficient, potentially making 60,000 patients a year eligible for the infused drug, which costs about $150,000 a year.

“At some point in the future — and it may be past my lifetime — if the immune system can be harnessed safely and effectively, there should be no need for surgery, radiation and traditional chemotherapy,” says Dr. Thomas George, associate director of clinical investigation at University of Florida Health Cancer Center. “The cancer should be permanently destroyed by a patient’s own immune system.”

 

See other stories from Florida Trend's March issue.

Get Florida Trend's March magazine – print or digital. Select from these options:

EXISTING
DIGITAL
SUBSCRIBERS

Access Article Now!

DIGITAL
SINGLE
ISSUE

Get a single DIGITAL copy of this issue

$4.95

PRINT
SINGLE
ISSUE

Get a single PRINT copy of this issue

$4.95
plus $3 postage & handling

PRINT SUBSCRIPTION

One year in PRINT

$14.98*
plus a FREE gift!

DIGITAL SUBSCRIPTION

One year DIGITAL

$14.98*
plus a FREE gift!

ALL ACCESS SUBSCRIPTION

One year Combo
PRINT + DIGITAL

$24.95*
plus a FREE gift!


CURRENT  PRINT  SUBSCRIBERS

If you are already a print subscriber,
ADD DIGITAL EDITION ACCESS
to your existing subscription here!
(or call our office at 727-892-2643)

* offer valid for new subscribers only

Tags: Government/Politics & Law, Healthcare, Life Sciences, Research & Development, Technology/Innovation, Cancer Care, Economic Backbone

Florida Business News

Florida News Releases

Florida Trend Video Pick

Facial recognition cameras in Florida city spark privacy concerns
Facial recognition cameras in Florida city spark privacy concerns

New security cameras in downtown Lakeland are raising concerns about privacy. The Lakeland Downtown Development Authority has begun installing 13 new security cameras on streets, sidewalks, and alleyways, and there are mixed feelings about them.

Video Picks | Viewpoints@FloridaTrend

Ballot Box

Should Congress ban the popular social media app TikTok in the U.S.?

  • Yes
  • No
  • Need more details
  • What is TikTok?
  • Other (Comment below)

See Results

Florida Trend Media Company
490 1st Ave S
St Petersburg, FL 33701
727.821.5800

© Copyright 2024 Trend Magazines Inc. All rights reserved.